Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN
Breast cancer remains the leading cancer burden in women, particularly in transitioning countries. Addressing this growing burden requires urgent integration of primary prevention, early detection and high-quality treatment through multi-sectoral collaboration.
Authors
- Yubei Huang (ORCID: https://orcid.org/0000-0002-6299-7112)
- Zhuowei Feng
- Fengju Song
- Zhangyan Lyu (ORCID: https://orcid.org/0000-0001-5833-1724)
- Lei Yang (ORCID: https://orcid.org/0000-0001-6946-9243)
- Yuting Ji (ORCID: https://orcid.org/0009-0005-1466-1920)
- Hongyuan Duan
- Yacong Zhang (ORCID: https://orcid.org/0000-0003-0708-940X)
- Yunmeng Zhang (ORCID: https://orcid.org/0000-0002-3069-9698)
- Fangfang Song (ORCID: https://orcid.org/0000-0003-3998-8506)
- Zhihong Liu (ORCID: https://orcid.org/0000-0001-6093-0726)
- Liu Ya
- Jingjing Li (ORCID: https://orcid.org/0000-0002-7664-887X)
- Siwen Liu (ORCID: https://orcid.org/0000-0002-0446-0448)
- Xiaomin Liu (ORCID: https://orcid.org/0000-0002-0827-5397)
- Jie Wu (ORCID: https://orcid.org/0000-0002-7400-2063)
- Qianyun Jin
Institutions
- Peking University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Peking University Cancer Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Journal of the National Cancer Center
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1016/j.jncc.2025.02.002
- Citations
- 67
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 70.04
Funders
- National Key Research and Development Program of China Stem Cell and Translational Research